Halberd Corporation Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein
Jackson Center, PA, December 23, 2020 – Halberd Corp. (OTC PINK: "HALB") research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein. Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd’s initial antibody. Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only the SARS-CoV-2 antigen) as well as a potential “cocktail mix” of both antibodies acting in concert. Halberd’s Chief Technical Officer, ...
Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19
Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month. The procedure is designed to treat infected blood which has been dosed with a specific antibody compound and then exposed to tuned radio ...
Halberd Corp. Research Yields Potent SARS-CoV-2 Antibody
Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication. Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based on these exciting findings, Halberd Corporation has commenced designing studies to establish the efficacy, specificity and sensitivity of the antibody. ...
Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast
Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company’s recent press release detailing promising SARS-CoV-2 laboratory testing. “Our primary technology is our ...
Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing
Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research. The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein. Scientific details of the testing to date will be released later this week. William Hartman, the CEO and President of commented, “Within the next two days we will ...
Halberd Corporation’s Covid-19 Technology Recognized by Momentum Observer
Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ). The article featured Halberd's nasal spray currently under development that could be an effective alternative to a vaccine against Covid-19. William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated, “Halberd is also working ...